» Articles » PMID: 38694489

Tacrolimus's Time Below Therapeutic Range Is Associated With Acute Pancreatic Graft Rejection and the Development of Donor-specific Antibodies

Abstract

Tacrolimus is pivotal in pancreas transplants but poses challenges in maintaining optimal levels due to recipient differences. This study aimed to explore the utility of time spent below the therapeutic range and intrapatient variability in predicting rejection and donor-specific antibody (dnDSA) development in pancreas graft recipients. This retrospective unicentric study included adult pancreas transplant recipients between January 2006 and July 2020. Recorded variables included demographics, immunosuppression details, HLA matching, biopsy results, dnDSA development, and clinical parameters. Statistical analysis included ROC curves, sensitivity, specificity, and predictive values. A total of 131 patients were included. Those with biopsy-proven acute rejection (BPAR, 12.2%) had more time (39.9% ± 24% vs. 25.72% ± 21.57%, = 0.016) and tests (41.95% ± 13.57% vs. 29.96% ± 17.33%, = 0.009) below therapeutic range. Specific cutoffs of 31.5% for time and 34% for tests below the therapeutic range showed a high negative predictive value for BPAR (93.98% and 93.1%, respectively). Similarly, patients with more than 34% of tests below the therapeutic range were associated with dnDSA appearance (38.9% vs. 9.4%, = 0.012; OR 6.135, 1.346-27.78). In pancreas transplantation, maintaining optimal tacrolimus levels is crucial. Suboptimal test percentages below the therapeutic range prove valuable in identifying acute graft rejection risk.

Citing Articles

Calcineurin inhibition may prevent Alzheimer disease in people with Down syndrome.

Dohl J, Treadwell Z, Norris C, Head E Alzheimers Dement. 2025; 21(3):e70034.

PMID: 40042516 PMC: 11881635. DOI: 10.1002/alz.70034.

References
1.
Gallagher H, Sarwar G, Tse T, Sladden T, Hii E, Yerkovich S . Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival. J Heart Lung Transplant. 2015; 34(11):1442-8. DOI: 10.1016/j.healun.2015.05.028. View

2.
Song T, Yin S, Jiang Y, Huang Z, Liu J, Wang Z . Increasing Time in Therapeutic Range of Tacrolimus in the First Year Predicts Better Outcomes in Living-Donor Kidney Transplantation. Front Immunol. 2020; 10:2912. PMC: 6933438. DOI: 10.3389/fimmu.2019.02912. View

3.
Whalen H, Glen J, Harkins V, Stevens K, Jardine A, Geddes C . High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime. Transplantation. 2016; 101(2):430-436. DOI: 10.1097/TP.0000000000001129. View

4.
Kuypers D . Intrapatient Variability of Tacrolimus Exposure in Solid Organ Transplantation: A Novel Marker for Clinical Outcome. Clin Pharmacol Ther. 2019; 107(2):347-358. DOI: 10.1002/cpt.1618. View

5.
Ventura-Aguiar P, Cabello M, Beneyto I, Navarro Cabello D, Tabernero G, Alonso A . Patient and graft survival in pancreas transplant recipients: The EFISPAN study. Nefrologia (Engl Ed). 2022; 43(1):133-143. DOI: 10.1016/j.nefroe.2022.11.019. View